Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

DelveInsight’s, “Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Extensive Stage Small Cell Lung Cancer Understanding

Extensive Stage Small Cell Lung Cancer: Overview

Extensive stage small cell lung cancer (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.

""Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Extensive Stage Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Extensive Stage Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Extensive Stage Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Extensive Stage Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Extensive Stage Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Extensive Stage Small Cell Lung Cancer.

Extensive Stage Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the Extensive Stage Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Extensive Stage Small Cell Lung Cancer Emerging Drugs

• LY 2510924: Eli Lilly and Company

LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY-2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

• Tiragolumab: Genentech

Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tiragolumab works as an immune amplifier, by potentially enhancing the body’s immune response. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell anti-tumor activity. It is in phase 3 stage of development for the treatment of Extensive-Stage Small Cell Lung Cancer.

Further product details are provided in the report……..

Extensive Stage Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Extensive Stage Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Extensive Stage Small Cell Lung Cancer

There are approx. 40+ key companies which are developing the therapies for Extensive Stage Small Cell Lung Cancer. The companies which have their Extensive Stage Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Extensive Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Extensive Stage Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Extensive Stage Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Extensive Stage Small Cell Lung Cancer drugs.

Extensive Stage Small Cell Lung Cancer Report Insights

• Extensive Stage Small Cell Lung Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Extensive Stage Small Cell Lung Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Extensive Stage Small Cell Lung Cancer drugs?
• How many Extensive Stage Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Extensive Stage Small Cell Lung Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Extensive Stage Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Extensive Stage Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• Genentech
• Bristol-Myers Squibb
• Henlix Biotech
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• BioNTech SE
• Xencor, Inc.
• Haihe Biopharma Co., Ltd.
• Taizhou HoudeAoke Biomedical Co., Ltd.
• Celgene
• MedImmune
• Xcovery Holding Company, LLC
• Lee's Pharmaceutical Limited
• Merck & Co
• Astex Pharmaceuticals

Key Products

• LY 2510924
• Tiragolumab
• BMS-986012
• Serplulimab
• SYHA1807
• BNT411
• XmAb18087
• Vorolanib
• AL3810
• LP002
• CC-90011
• Tremelimumab
• Ipilimumab
• ZKAB001
• Pembrolizumab
• Guadecitabine